Therefore, Hsp90 demonstrated advantages in overcoming drug resistance as a broad-spectrum anti-cancer target, which would be another choice for NSCLC patients with drug resistance. This evidence concerns the gene HSP90AA1 and non-small cell lung carcinoma.